Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maria Fonfria"'
Autor:
Inmaculada de Juan Jiménez, Eduardo Martinez-Dueńas, Maria Fonfria, Ana Beatriz Sánchez-Heras, Isabel Chirivella, Paula Richart-Aznar, Ángel Segura, Isabel Tena
Publikováno v:
Journal of Personalized Medicine
Volume 11
Issue 6
Journal of Personalized Medicine, Vol 11, Iss 548, p 548 (2021)
Volume 11
Issue 6
Journal of Personalized Medicine, Vol 11, Iss 548, p 548 (2021)
(1) Background: Over the last decade, genetic counseling clinics have moved from single-gene sequencing to multigene panel sequencing. Multiple genes related to a moderate risk of breast cancer (BC) have emerged, although many questions remain regard
Autor:
Isabel Tena, Garima Gupta, Marcos Tajahuerce, Marta Benavent, Manuel Cifrián, Alejandro Falcon, María Fonfria, Maribel del Olmo, Rosa Reboll, Antonio Conde, Francisca Moreno, Julia Balaguer, Adela Cañete, Rosana Palasí, Pilar Bello, Alfredo Marco, José Luis Ponce, Juan Francisco Merino, Antonio Llombart, Alfredo Sanchez, Karel Pacak
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 12 (2018)
Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B ( SDHB ) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/P
Externí odkaz:
https://doaj.org/article/5c24168471b54ef793ab1cca8105515d
Autor:
Joan Manel Gasent Blesa, Sara Blasco Mollá, María Fonfría Esparcia, JoséMiguel Sempere Ortells, Miguel Peris Godoy, Adrian Munilla Das, Balbino Mancheño Magan, Mariano Provencio Pulla, Jose Luis Sanchez, Juan Bautista Laforga Canales, Vicente Alberola Candel
Publikováno v:
Case Reports in Oncology, Vol 5, Iss 3, Pp 676-681 (2012)
Treatment of a relapsed glioma is a clinical challenge nowadays. New active treatments are required to treat these difficult diseases. Here we present a durable complete remission of a relapsed glioblastoma that has achieved a complete radiologic res
Externí odkaz:
https://doaj.org/article/e3815badee514242a3b5fc23ae191ff7
Autor:
Joan Manel Gasent Blesa, Miguel Peris Godoy, María Fonfría Esparcia, Sara Blasco Mollá, Balbino Mancheño Magán, JoséMiguel Sempere Ortells, JoséLuis Sánchez
Publikováno v:
Case Reports in Oncology, Vol 5, Iss 1, Pp 181-186 (2012)
Hormone-resistant prostate cancer (HRPC) occurs when prostate cancer is no longer responsive to hormone therapy. Treatment options are limited, and there is a clear necessity for therapies that improve outcome. Preclinical and clinical evidence suppo
Externí odkaz:
https://doaj.org/article/69802955e1344ba4926295fddc2d4f57